Avacta Group has confirmed that Moderna has disclosed Phase I trial data for its mRNA technology.

It says this is the first public evidence that it works, which meaningfully de-risks the partnership plans to deliver Affimer therapeutics using mRNA.


Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents.

Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations.

Moderna was the first to enter into an agreement with Avacta to use the Affimer technology, in tandem with Moderna's mRNA drug delivery platform.

At 1:32pm: (LON:AVCT) Avacta Group PLC share price was -0.5p at 86p